Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 7/20 | 0.69 |
| ▸ | CBFB | Q13951 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525960 | 0.90 | RUNX1 (0.84) | RUNX1CBFBP2RY1DHODHIDO1 | |
| SCHEMBL17525975 | 0.88 | RUNX1 (0.68) | RUNX1CBFBP2RY1DHODHIDO1 | |
| SCHEMBL179102 | 0.82 | CBFB (0.82) | RUNX1CBFBP2RY1 | |
| SCHEMBL179096 | 0.81 | CBFB (0.63) | RUNX1CBFBP2RY1 | |
| SCHEMBL179101 | 0.81 | CBFB (0.63) | RUNX1CBFBP2RY1 | |
| SCHEMBL17525962 | 0.79 | RUNX1 (0.62) | RUNX1CBFB | |
| SCHEMBL17525963 | 0.78 | RUNX1 (0.84) | RUNX1CBFBP2RY1 | |
| SCHEMBL21727103 | 0.78 | RUNX1 (0.63) | RUNX1CBFBP2RY1IDO1KDM4E | |
| SCHEMBL17525976 | 0.76 | CBFB (0.56) | RUNX1CBFB | |
| SCHEMBL15391762 | 0.75 | TRPV1 (0.53) | RUNX1DHODHKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016025744-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | RUNX1 1/4885CBFB 2/4885CHEK2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.